Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000577:Amides; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011720:Pyrazoles; D012263:Ribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D012266:Ribose
D000577:Amides; D000903:Antibiotics, Antineoplastic; D011720:Pyrazoles; D012263:Ribonucleosides; C002997:pyrazofurin; D012266:Ribose